Migraine treatments that target calcitonin gene-related peptide (CGRP) are widely used, but questions remain regarding their mechanisms and sites of action. Re-examination of the effects of CGRP in the trigeminovascular system has now refined our understanding of nociceptive CGRP signalling and underscores the importance of early therapeutic intervention.
Melo-Carrillo, A., Strassman, A. & Burstein, R.
Elucidating the nociceptive role of CGRP in migraine headache. Brain https://doi.org/10.1093/brain/awag008 (2026).
Pedersen-Bjergaard, U. et al.
Calcitonin gene-related peptide, neurokinin A and substance P: effects on nociception and neurogenic inflammation in human skin and temporal muscle. Peptides 12 , 333–337 (1991).
Levy, D., Burstein, R. & Strassman, A.
M. Calcitonin gene–related peptide does not excite or sensitize meningeal nociceptors: Implications for the pathophysiology of migraine.
Ann. Neurol.
58 , 698–705 (2005). Melo-Carrillo, A.
et al. Novel insight into atogepant mechanisms of action in migraine prevention.
Brain 147 , 2884–2896 (2024). Strassman, A.
M. & Levy, D.
Response properties of dural nociceptors in relation to headache. J.
Neurophysiol. 95 , 1298–1306 (2006).
Covasala, O., Stirn, S. L., Albrecht, S., De Col, R.
& Messlinger, K.
Nature Reviews Neurology published a clinical update in Neurology on 27 Apr 2026.
The item focuses on Nociceptive action of calcitonin gene-related peptide in the trigeminovascular system.
Review the original article for the full source wording and details.